fbpx

Day

november 30, 2016
Vtesse announced early in 2016 that the FDA granted Breakthrough Therapy designation status for VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial in NPC. Both the FDA and the European Medicines Agency (EMA) previously granted Orphan Drug status to VTS-270, and the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted...

Nyheder

Syv forskningsinstitutioner får 20 mio. kr. til corona-forskning
1. april 2020
Sådan håndterer vi ændring af forskningsprojekter under corona-pandemien
31. marts 2020
Første Corona-bevilling fra Lundbeckfonden til forsøg med et kendt lægemiddel
26. marts 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge